Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NYSE: BIO

Bio-Rad Laboratories, Inc.

Healthcare | Medical - Devices

Market prices for BIO are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$8.19

Bio-Rad Laboratories, Inc. (NYSE: BIO) is a medical device company. Figures from SEC EDGAR; updated 2026-10-20 17:29 UTC.

What Bio-Rad Laboratories, Inc. does

Bio-Rad Laboratories is a multinational company that develops, manufactures, and markets instruments, systems, reagents, and consumables for life science research and clinical diagnostics. The company operates through two segments: Life Science, which serves research institutions and biopharmaceutical manufacturers with products for separating and analyzing biological materials, and Clinical Diagnostics, which supplies test systems and reagents to clinical laboratories worldwide.

Summarized from Bio-Rad Laboratories, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$8.19
Return on equity10.20%
Debt/equity0.17

Revenue, margins & earnings

FY2021 Revenue: $2.92B — margin split not shown (non-operating gains)FY2021: net income $4.25B exceeded revenue $2.92B by $1.33B — non-operating gains (e.g. asset sales), not operating profit$2.92BFY2021FY2022: net loss $3.63B on revenue $2.80B$2.80BFY2022FY2023: net loss $637M on revenue $2.67B$2.67BFY2023FY2024: net loss $1.84B on revenue $2.57B$2.57BFY2024FY2025 Revenue: $2.58B — margin split not shown (non-operating gains)$2.58BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net income above revenue (non-operating gains)
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →
Gold cap: net income exceeded revenue that year from non-operating gains (e.g. asset sales), not operating profit.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-09
  • 2026-09-09EVP, Global Supply ChainRestricted Stock UnitsOption exercise-1,027—
  • 2026-09-09President & COOTax withholding-668$257.9K
  • 2026-09-09EVP, President, LSGOption exercise1,027—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Bio-Rad Laboratories, Inc. do?

Bio-Rad Laboratories is a multinational company that develops, manufactures, and markets instruments, systems, reagents, and consumables for life science research and clinical diagnostics.

When did BIO last file with the SEC?

Bio-Rad Laboratories, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-08-04. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 17:29 UTC. This page is also available as JSON at /api/data?ticker=BIO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BIO and 5,000+ tickers.

Create a free account — keep BIO
For your agent
GET /api/data?ticker=BIO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt